Eli Lilly and Company (NYSE:LLY) Stock Holdings Reduced by OLD National Bancorp IN

OLD National Bancorp IN lowered its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 0.4% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 610,575 shares of the company's stock after selling 2,265 shares during the quarter. Eli Lilly and Company accounts for approximately 13.3% of OLD National Bancorp IN's investment portfolio, making the stock its biggest holding. OLD National Bancorp IN owned 0.06% of Eli Lilly and Company worth $504,280,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of LLY. FPC Investment Advisory Inc. boosted its holdings in Eli Lilly and Company by 358.3% in the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after buying an additional 43 shares during the period. Mascagni Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company during the fourth quarter worth about $43,000. Prudent Man Investment Management Inc. purchased a new position in Eli Lilly and Company in the 4th quarter worth approximately $48,000. Compass Financial Services Inc bought a new position in Eli Lilly and Company in the fourth quarter valued at $50,000. Finally, Capital A Wealth Management LLC purchased a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $63,000. 82.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have weighed in on LLY shares. Cantor Fitzgerald initiated coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price target for the company. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their price objective for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Morgan Stanley reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Guggenheim reissued a "buy" rating on shares of Eli Lilly and Company in a research note on Friday, May 23rd. Finally, Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $1,011.37.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.14% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY traded up $0.78 during midday trading on Wednesday, hitting $807.97. The company had a trading volume of 3,114,319 shares, compared to its average volume of 3,652,825. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The company has a fifty day moving average of $770.33 and a two-hundred day moving average of $800.86. The company has a market cap of $765.74 billion, a price-to-earnings ratio of 69.00, a PEG ratio of 1.40 and a beta of 0.41. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same period last year, the company earned $2.58 EPS. The business's revenue was up 45.2% on a year-over-year basis. On average, equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th were given a dividend of $1.50 per share. The ex-dividend date was Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.74%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.